In this session we will describe the exciting transformation of the endometrial cancer landscape in the last several years, moving to molecular classification for aid in pathological categorization and providing prognostic and predictive information with which to guide management and clinical trials. Strategies for implementation of molecular classification in both low and high resource settings will be shared, as well as when additional molecular or pathological parameters might add value. Current challenges or as yet unanswered questions in endometrial cancer management will be addressed.

This session consists of four oral abstract presentations followed by distillations by renowned speakers.